

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALOXONE)
ANTITRUST LITIGATION

MDL NO. 2445
13-MD-2445

THIS DOCUMENT RELATES TO:,

Wisconsin, et al. v. Indivior Inc. et al.
Case No. 16-cv-5073

STATE OF WISCONSIN
By Attorney General Brad D. Schimel, et al.

CIV. A. NO. 16-5073

Plaintiffs,

v.

INDIVIOR INC. f/k/a RECKITT BENCKISER
PHARMACEUTICALS, INC., et al.

Defendants.

ORDER

AND NOW, this 19th day of October, 2022, upon consideration of the Motion for Summary Judgment by Defendant Aquestive Therapeutics, Inc. (“Aquestive”) (MDL No. 13-2445, Doc. Nos. 702, 704; Civ. A. No. 16-5073, Doc No. 452), the Response by Plaintiffs State of Wisconsin, et al. (“States”) (MDL No. 13-2445, Doc. Nos. 726, 729; Civ. A. No. 16-5073, Doc Nos. 460, 466), Aquestive’s Reply (MDL No. 13-2445, Doc. Nos. 744, 750; Civ. A. No. 16-5073, Doc No. 472), and the States’ Sur-reply (MDL No. 13-2445, Doc. Nos. 757, 758; Civ. A. No. 16-5073, Doc Nos. 477, 478), and following oral argument on the Motion, it is hereby **ORDERED** that the Motion is **GRANTED**.

JUDGMENT IS ENTERED in favor of Defendant Aquestive Therapeutics, Inc. and against Plaintiff States on all claims against Aquestive.

BY THE COURT:

/s/ Mitchell S. Goldberg
MITCHELL S. GOLDBERG, J.